

BELKYRA® EXPLAINED

A treatment to improve the appearance of a double chin.



Double chin defined

Fullness under the chin or a 'double chin' is a common concern for both men and women. It can be caused by:



AGEING

It may naturally develop as you age



GENETICS

Simply said, it may be part of your DNA



WEIGHT CHANGES

It may appear as a result of weight change

Sometimes, no matter how much you diet or exercise, the fullness in this area may not go away – and it may make you feel like you look older and heavier than you actually are.

How BELKYRA® works

The active ingredient in BELKYRA® is synthesised deoxycholic acid. Deoxycholic acid also occurs naturally in the body where it helps to break down dietary fat.

When injected below the chin, BELKYRA® reduces fat, resulting in a more contoured neck profile and jawline.

As it is a prescription-only medicine, BELKYRA® treatment is only available from your clinician.

BELKYRA[®] is an injectable treatment that improves **the appearance of a double chin.**



BELKYRA® Treatment

- The injectable treatment will be completed in your clinician's office and should take approximately 15–20 minutes
- Your clinician will customise the treatment to your individual anatomy and circumstances
- The procedure is a not surgical treatment
- Once your desired results are achieved, re-treatment is not expected as results are maintained for at least 4 years

Results with BELKYRA®

Many people treated with BELKYRA[®] experienced visible improvement in the appearance of their chin profile in 2–4 treatments.

Up to 6 treatments may be administered, spaced at least 4 weeks apart.

What does treatment involve?

BELKYRA® is typically given in a 15- to 20-minute in-office treatment session. Your clinician will administer a series of injections into the area under your chin at each session.

How many treatments will I need?

Many patients treated with BELKYRA® experience visible improvement of their chin profile in 2–4 treatments. Some people require up to 6 treatments in order to achieve their best results. Once your desired results are achieved, additional treatments may not be needed as results are maintained for at least 4 years.

Are there any side effects?

As with other injectable treatments, you may experience side effects with BELKYRA[®]. Most patients experience mild or moderate pain or discomfort at the time BELKYRA[®] is injected.

Tell your clinician if you notice any of the following:

- bruising pain
- numbness
- swellingtingling
- redness
- formation of small areas of hardness
- itching around the treatment area

While unlikely, talk to your clinician if you experience any of the following: trouble swallowing, an uneven smile, taste disturbances, or discolouration, unusual hair loss or an ulcer (open sore) at the site of injection.



What can I expect during treatment?

Prior to administering BELKYRA®, your clinician may apply ice/cold packs or topical and/or injectable local anaesthesia (e.g. lidocaine) to the treatment area to make you more comfortable. They may also suggest that you take an over-the-counter pain medication before your appointment.

Post-treatment

Your clinician will have reviewed with you what to expect following your BELKYRA® treatment.

Additional Instructions

It is recommended that you attend a review appointment after 4 weeks so that your clinician can assess the outcome of your treatment.

Your follow-up appointment

_____ /____ /_____ at _____ am/pm

To follow your results and for other documentation reasons, you may be photographed and the results recorded in your confidential patient file.

Your next BELKYRA® treatment appointment

_____ /_____ at _____ am/pm

If you have any questions or concerns about your BELKYRA® treatment, please contact your clinician.



BELKYRA[®] and its design are trademarks of Kythera Biopharmaceuticals, Inc., an Allergan affiliate. [™]Trademark of Allergan, Inc. Allergan Australia Pty Ltd, 810 Pacific Highway, Gordon NSW 2072. ABN 85 000 612 831. © 2017 Allergan. All rights reserved. Date of preparation: January 2017. ANZ/0134/2016. ALBK12029. Ward6.